06/17/2026
Retatrutide is one of the most closely watched medications in the metabolic health space. It’s a triple receptor agonist, meaning it targets GIP, GLP-1, and glucagon receptors—and recent Phase 3 data showed major weight-loss potential at the highest dose. It’s also being studied for obesity-related conditions including knee osteoarthritis pain, obstructive sleep apnea, MASLD, and cardiovascular/renal outcomes.
Important warning: this is a powerful investigational medication and should only be used under physician supervision once approved and prescribed appropriately. Compounded or gray-market versions can be risky—especially with a drug this strong.
Please don’t DIY this.
👉 For evidence-based metabolic care, book via the link in bio.
Educational only; not medical advice.